1. Inicio
  2. Publicaciones
  3. Epidemiological and Therapeutic Profile in Atopic Dermatitis According to the Involvement on Special Locations. Spanish Atopic Dermatitis Registry (BIOBADATOP)

Epidemiological and Therapeutic Profile in Atopic Dermatitis According to the Involvement on Special Locations. Spanish Atopic Dermatitis Registry (BIOBADATOP)

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Bassets-Gonzalvo N.
  • Munera-Campos M.
  • Ruiz-Villaverde R.
  • Silvestre-Salvador J.F.
  • Espasandín-Arias M.
  • Lasheras-Pérez M.-A.
  • González-Quesada A.
  • Gilaberte-Calzada Y.
  • de la Cueva Dobao P.
  • Chicharro P.
  • Pereyra-Rodríguez J.J.
  • Herrera-Acosta E.
  • Montero-Vilchez T.
  • Elosua-González M.
  • Bertolín-Colilla M.
  • Prat-Colilles E.
  • Navarro-Triviño F.J.
  • Betlloch-Mas I.
  • Batalla A.
  • Castaño-González I.
  • Alonso-Suárez J.
  • Arias-Santiago S.
  • Roustan G.
  • Curto-Barredo L.
  • Ruiz-Carrascosa J.C.
  • Couselo-Rodríguez C.
  • Sanabria-de la Torre R.
  • Rosell-Díaz Á.M.
  • Giménez-Arnau A.M.
  • Martínez-Fernández S.
  • Garcia-Doval I.
  • Descalzo-Gallego M.-A.
  • Carrascosa J.-M.

Grupos

Abstract

Background The development of new therapies for atopic dermatitis (AD) has represented a qualitative leap in disease control. However, involvement of special locations (SL) may pose a challenge, given its association with a high impact on quality of life that is not always related to objective extension. Material and methods We used the BIOBADATOP registry (Spanish AD Registry). We conducted a descriptive analysis of the epidemiology of SL involvement, as well as its therapeutic and prognostic implications. Three areas were defined as SL: the face, genitals, and hands. Patients were grouped according to the absence of involvement, involvement of one SL, or involvement of =2 SLs. Results Of the 616 patients included, 70% presented facial involvement, 46.6% hand involvement, and 28.2% genital involvement. Among adults (82.1%; N = 506), 23.7% presented involvement of 1 SL and 52.8% involvement of =2SLs. Greater SL involvement was associated with a higher number of previous systemic treatments and higher baseline EASI and POEM scores, among other findings. In the pediatric group (17.9%; N = 110), 30% presented involvement of 1 SL and 45.5% involvement of =2 SLs. A greater number of previous treatments was also recorded compared with patients without SL involvement. Conclusions Involvement of SLs tends to be associated with greater baseline severity and a higher number of previous systemic treatments, a circumstance that should be taken into consideration in the management of these patients. . © 2026 AEDV.

Datos de la publicación

ISSN/ISSNe:
0001-7310, 1578-2190

Actas Dermo-Sifiliograficas  ELSEVIER ESPANA

Tipo:
Article
Páginas:
-
PubMed:
42142838
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,279 SCImago ℠
Cuartil:
Q3 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • abrocitinib; baricitinib; corticosteroid; cyclosporine; dupilumab; methotrexate; tralokinumab; upadacitinib; adolescent; adult; Article; atopic dermatitis; child; clinical feature; clinical outcome; cohort analysis; comorbidity; comparative study; controlled study; correlation analysis; disease registry; disease severity; Eczema Area and Severity Index; epidemiological data; face; female; follow up; genital system; hand; human; major clinical study; male; multicenter study; observational study; Patient Oriented Eczema Measure Score; pediatric patient; prognosis; prospective study; quality of life; scoring system; systemic therapy; treatment response

Cita

Compartir